Moomoo AI 已提取核心訊息
On January 8, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced two significant developments. Firstly, the company disclosed that it had regained compliance with the Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price requirement. This follows a previous notification on November 3, 2023, indicating that Compugen's shares had fallen below the $1.00 minimum bid price over 30 consecutive business days. The company successfully maintained a closing bid price of at least $1.00 for 10 consecutive business days from December 19, 2023, to January 3, 2024, which led to the restoration of compliance. Secondly, Compugen revealed that it is set to receive a $10 million milestone payment from AstraZeneca. This payment was triggered by the dosing of the first patient in AstraZeneca's Phase 3 trial of rilvegostomig for biliary tract cancer. Rilvegostomig is a PD-1/TIGIT bispecific antibody developed from Compugen's COM902 antibody, which is part of a licensing agreement with AstraZeneca for the development of bispecific and multispecific antibodies. Compugen specializes in computational target discovery for cancer immunotherapies and has a pipeline of proprietary and partnered therapeutic programs.
On January 8, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced two significant developments. Firstly, the company disclosed that it had regained compliance with the Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price requirement. This follows a previous notification on November 3, 2023, indicating that Compugen's shares had fallen below the $1.00 minimum bid price over 30 consecutive business days. The company successfully maintained a closing bid price of at least $1.00 for 10 consecutive business days from December 19, 2023, to January 3, 2024, which led to the restoration of compliance. Secondly, Compugen revealed that it is set to receive a $10 million milestone payment from AstraZeneca. This payment was triggered by the dosing of the first patient in AstraZeneca's Phase 3 trial of rilvegostomig for biliary tract cancer. Rilvegostomig is a PD-1/TIGIT bispecific antibody developed from Compugen's COM902 antibody, which is part of a licensing agreement with AstraZeneca for the development of bispecific and multispecific antibodies. Compugen specializes in computational target discovery for cancer immunotherapies and has a pipeline of proprietary and partnered therapeutic programs.
2024年1月8日，臨床階段的癌症免疫療法公司Compugen有限公司宣佈了兩項重大進展。首先，該公司透露已恢復遵守納斯達克上市規則5550（a）（2）中關於最低出價要求的要求。在此之前，Compugen於2023年11月3日發佈了一份通知，表明Compugen的股票在連續30個工作日內跌破了1.00美元的最低出價。從2023年12月19日至2024年1月3日，該公司成功地連續10個工作日將收盤價維持在至少1.00美元，這導致合規性恢復。其次，Compugen透露，它將從阿斯利康獲得1000萬美元的里程碑式付款。這筆付款是由阿斯利康針對膽道癌的rilvegostomig三期試驗中第一位患者給藥...展開全部
2024年1月8日，臨床階段的癌症免疫療法公司Compugen有限公司宣佈了兩項重大進展。首先，該公司透露已恢復遵守納斯達克上市規則5550（a）（2）中關於最低出價要求的要求。在此之前，Compugen於2023年11月3日發佈了一份通知，表明Compugen的股票在連續30個工作日內跌破了1.00美元的最低出價。從2023年12月19日至2024年1月3日，該公司成功地連續10個工作日將收盤價維持在至少1.00美元，這導致合規性恢復。其次，Compugen透露，它將從阿斯利康獲得1000萬美元的里程碑式付款。這筆付款是由阿斯利康針對膽道癌的rilvegostomig三期試驗中第一位患者給藥引發的。Rilvegostomig是一種由Compugen的 COM902 抗體開發的PD-1/TIGIT雙特異性抗體，該抗體是與阿斯利康簽訂的開發雙特異性和多特異性抗體的許可協議的一部分。Compugen專門研究癌症免疫療法的計算靶標發現，並擁有一系列專有和合作的治療項目。
有用
沒用